Is there a specific “BMS 2000” dasatinib patent?
The name “BMS 2000” is not a standard, widely used patent term for dasatinib in the information provided here. Dasatinib is marketed by Bristol Myers Squibb under the brand Sprycel, but patents are filed under legal applicant names and patent publication numbers—not usually as informal product codes like “BMS 2000.”
If you meant “Which patent covers dasatinib (Sprycel) by Bristol Myers Squibb?” or “When does the dasatinib patent expire?”, you’ll need the exact patent publication number or filing details (for example, an EP/WO/US publication) to answer precisely.
Which patents typically cover dasatinib (Sprycel)?
Dasatinib patent protection commonly includes different layers:
- compound/patent claims on the drug substance (the active ingredient)
- formulation/process patents (how it’s made or delivered)
- use/patent claims (specific dosing regimens or indications, depending on the jurisdiction)
Because expiration depends on claim scope and jurisdiction, the relevant publication number matters.
When does dasatinib patent protection expire?
Patent expiry is jurisdiction-specific (US vs. EP/WO vs. other countries) and can be extended by mechanisms like pediatric extensions or regulatory exclusivity, depending on filing dates and local rules. To give an accurate expiry timeline, you must identify the specific dasatinib patent (publication number or jurisdiction).
What to do if you have the “BMS 2000” identifier
If “BMS 2000” comes from a label, spreadsheet, dossier, or a listing you saw, share one of the following and the patent question can be answered precisely:
- the US/EP/WO publication number
- the patent number (e.g., “USxxxxxxx” or “EPxxxxxxx”)
- the country/jurisdiction and approximate year
- a link or screenshot text containing “BMS 2000”
Once you provide that, it’s possible to map it to the correct dasatinib patent family and give the expected expiry/exclusivity date for that jurisdiction.
Are you asking about biosimilars/generics timing for dasatinib?
If your real goal is “Can generics enter yet?” that depends on:
- whether the relevant compound/formulation/use patents are still in force
- any market exclusivity periods granted in that country
- litigation status (if any) tied to those patents
To answer accurately, you’d again need the exact patent identifiers or at least the country you care about (e.g., US vs. UK vs. EU member states).
Quick clarification request
What does “BMS 2000” refer to in your source?
Please paste the patent number/publication number (or the link/text where you saw “BMS 2000”), and tell me which jurisdiction (US, EU/EP, WO, etc.).